We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
(+5%)
Cap. Flow
+$1.13B
Cap. Flow
% of AUM
11.96%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$51.9M |
| 2 |
Merck
MRK
|
+$50.9M |
| 3 |
Danaher
DHR
|
+$45.3M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$37.8M |
| 5 |
JD.com
JD
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$103M |
| 2 |
Alibaba
BABA
|
+$98.6M |
| 3 |
Salesforce
CRM
|
+$62.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$59.4M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$48.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.61% |
| 2 | Technology | 20.94% |
| 3 | Consumer Discretionary | 8.9% |
| 4 | Financials | 8.59% |
| 5 | Communication Services | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Autoliv
ALV
$9.09B
| $346K | ﹤0.01% |
5,360
-3,744
| -41% | -$225K |
|
702
Digital Turbine
APPS
$1.02B
| $343K | ﹤0.01% |
+27,300
| New | +$191K |
|
703
Altria Group
MO
$125B
| $341K | ﹤0.01% |
8,700
+520
| +6% | +$20.3K |
|
704
Federal Realty Investment Trust
FRT
$10.9B
| $332K | ﹤0.01% |
3,892
-5,531
| -59% | -$447K |
|
705
Zscaler
ZS
$24.5B
| $312K | ﹤0.01% |
+2,850
| New | +$237K |
|
706
Fortune Brands Innovations
FBIN
$6.09B
| $309K | ﹤0.01% |
5,664
-94,793
| -94% | -$4.41M |
|
707
Mohawk Industries
MHK
$7.14B
| $309K | ﹤0.01% |
3,039
+260
| +9% | +$22.9K |
|
708
Gaotu Techedu
GOTU
$384M
| $300K | ﹤0.01% |
+5,000
| New | +$198K |
|
709
UDR
UDR
$12.7B
| $290K | ﹤0.01% |
7,763
+225
| +3% | +$8.4K |
|
710
Ingredion
INGR
$6.48B
| $283K | ﹤0.01% |
+3,405
| New | +$279K |
|
711
iShares US Pharmaceuticals ETF
IHE
$1.5B
| $277K | ﹤0.01% |
+5,400
| New | +$271K |
|
|
DRE
712
DELISTED
Duke Realty Corp.
DRE
| $266K | ﹤0.01% |
7,517
+695
| +10% | +$23.7K |
|
713
Petrobras
PBR
$116B
| $258K | ﹤0.01% |
31,230
-128,065
| -80% | -$928K |
|
714
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| $254K | ﹤0.01% |
2,265
-865
| -28% | -$85.2K |
|
715
Fox Class A
FOXA
$24.2B
| $253K | ﹤0.01% |
9,425
-20,741
| -69% | -$560K |
|
716
Voya Financial
VOYA
$9.07B
| $248K | ﹤0.01% |
5,318
-2,765
| -34% | -$123K |
|
|
MRO
717
DELISTED
Marathon Oil Corporation
MRO
| $248K | ﹤0.01% |
40,556
-111,402
| -73% | -$616K |
|
718
Gold Fields
GFI
$29.2B
| $239K | ﹤0.01% |
25,433
-2,005
| -7% | -$15.2K |
|
719
Cemex
CX
$17.3B
| $234K | ﹤0.01% |
81,075
-3,000
| -4% | -$7.04K |
|
720
RTX Corp
RTX
$295B
| $234K | ﹤0.01% |
3,800
-104,022
| -96% | -$6.49M |
|
721
Shinhan Financial Group
SHG
$32.8B
| $232K | ﹤0.01% |
9,648
-4,642
| -32% | -$114K |
|
722
Lear
LEA
$7.45B
| $221K | ﹤0.01% |
2,023
-59,759
| -97% | -$5.95M |
|
|
ZEN
723
DELISTED
ZENDESK INC
ZEN
| $219K | ﹤0.01% |
+2,470
| New | +$190K |
|
724
KB Financial Group
KB
$40.6B
| $209K | ﹤0.01% |
7,513
-5,134
| -41% | -$140K |
|
|
TPC
725
Tutor Perini Cor
TPC
$4.31B
| $207K | ﹤0.01% |
+17,000
| New | +$152K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2020 Portfolio in Review
As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.
- Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
- Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
- Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
- Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
- Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
- Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
- Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.
Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.